- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Trial completion: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - Oct 10, 2023
P3, N=576, Completed,
Active, not recruiting --> Completed
- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - May 13, 2022
P3, N=576, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Feb 2022 --> Nov 2021 | Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Sep 2022
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Journal: Characterization of Phytochemicals in Ulva intestinalis L. and Their Action Against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. (Pubmed Central) - Oct 20, 2021
The results indicated that mainly phenols, polyenes, phytosteroids, and aliphatic compounds from the extract, such as 2,4-di-tert-butylphenol (2,4-DtBP), doconexent, 4,8,13-duvatriene-1,3-diol (DTD), retinoyl-β-glucuronide 6',3'-lactone (RBGUL), and retinal, showed better binding affinity to the target. Pharmacokinetic validation narrowed the list to 2,4-DtBP, retinal and RBGUL as the possible antiviral candidates that could inhibit the viral spike protein effectively.
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Preclinical, Journal: SC411 treatment can enhance survival in a mouse model of sickle cell disease. (Pubmed Central) - May 29, 2021
In summary, this study suggests that treatment with SC411 improves cellular and functional outcomes in SCD mice. This finding may provide novel therapeutic opportunities in the treatment against ischemic injury elicited by SCD.
- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Enrollment open, Trial completion date: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - Nov 17, 2020
P3, N=560, Recruiting,
This finding may provide novel therapeutic opportunities in the treatment against ischemic injury elicited by SCD. Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Apr 2022
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Trial completion date, Trial primary completion date: SCOT: A Sickle CEll Disease ComplicatioN Trial (clinicaltrials.gov) - Feb 1, 2019
P3, N=210, Not yet recruiting,
This trial was registered at www.clinicaltrials.gov as #NCT02973360. Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Dec 2020
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Trial completion date: Dose-Finding Study of SC411 in Children With Sickle Cell Disease (clinicaltrials.gov) - Jan 31, 2019
P2, N=68, Active, not recruiting,
Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Dec 2020 Trial completion date: Jul 2019 --> Jan 2022
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Trial initiation date, Trial primary completion date: SCOT: A Sickle CEll Disease ComplicatioN Trial (clinicaltrials.gov) - Oct 5, 2017
P3, N=213, Not yet recruiting,
Trial completion date: Oct 2018 --> Jul 2019 Initiation date: Jul 2017 --> Jan 2018 | Trial primary completion date: May 2019 --> Jan 2020
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Enrollment closed: Dose-Finding Study of SC411 in Children With Sickle Cell Disease (clinicaltrials.gov) - Jul 31, 2017
P2, N=68, Active, not recruiting,
Initiation date: Jul 2017 --> Jan 2018 | Trial primary completion date: May 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Trial initiation date, Trial primary completion date: SCOT: A Sickle CEll Disease ComplicatioN Trial (clinicaltrials.gov) - Nov 23, 2016
P3, N=213, Not yet recruiting,
Not yet recruiting --> Recruiting Initiation date: Jan 2016 --> Jul 2017 | Trial primary completion date: Dec 2017 --> May 2019
- |||||||||| Altemia (docosahexaenoic acid) / Micelle BioPharma
Enrollment change: SCOT: A Sickle CEll Disease ComplicatioN Trial (clinicaltrials.gov) - Dec 12, 2015
P3, N=213, Not yet recruiting,
Initiation date: Jan 2016 --> Jul 2017 | Trial primary completion date: Dec 2017 --> May 2019 N=162 --> 213
|
